DrugPatentWatch

DrugPatentWatch Archives

You are currently viewing the 2009 archives
Click here to return to the current data set

Search for Generic Name: CLOPIDOGREL BISULFATE

Summary for Generic Name: CLOPIDOGREL BISULFATE

Tradenames:2
Patents:4
Applicants:2
NDAs:2
Therapeutic Class:Blood Products/Modifiers/ Volume Expanders

Tentative approvals for CLOPIDOGREL BISULFATE

Applicant Application No. Form Dosage
TABLET; ORALEQ 75MG BASE
TABLET; ORAL75MG
TABLET; ORAL75MG

Glossary
Applicant Tradename Generic Name NDA Approval Date Type RLD Patent Number Product Substance Delist Req. Patent Expiration Exclusivity Expiration
Dr Reddys Labs IncCLOPIDOGREL BISULFATEclopidogrel bisulfate076273Jan 14, 2008DISCNNo
Sanofi Aventis UsPLAVIXclopidogrel bisulfate020839Nov 17, 1997RXNoAug 17, 2009
Sanofi Aventis UsPLAVIXclopidogrel bisulfate020839Nov 17, 1997RXNo4,847,265YYNov 17, 2011
Export available with Ultimate Plan subscription: 

This preview shows a limited data set. Complete access is available with a Subscription

<- Back to Dashboard


Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright © 2000-2010, thinkBiotech LLC.


[ Home | Site Tour | Plan Comparison | Free Patent Expiration Newsletter | Patent Inventor Report | Contact ]
Drug Patent ExpirationsFollow DrugPatentWatch on Twitter
Bookmark or Share This Page ...
[del.icio.us] [Digg] [Reddit] [Facebook] [LinkedIn] [StumbleUpon] [Technorati] [Twitter] [Email]